-
News | 2023.11.23
The 40-year fight against HIV: we speak to Marc Dixneuf, CEO of AIDES
In 1983 the AIDS virus, HIV, was isolated by virologists at the Institut Pasteur. Forty years later, HIV-positive patients can live with the virus if they are diagnosed in time and receive the right treatment. Treatments are constantly being improved – great strides are being made as a result of close cooperation between patients, caregivers and scientists. They are the bedrock of the 40-year...
-
News | 2023.12.20
Hepatitis B: using mathematics to reveal the best treatment model in The Gambia
To accelerate momentum in the global fight against hepatitis B, expanding testing and treatment services in resource-limited countries is crucial, especially in sub-Saharan Africa. But determining which patients are eligible for treatment is a complex process and requires tests that are not widely accessible in these regions. Should all people infected with the virus be treated without assessing...
-
News | 2024.06.11
Strengthening Multisectoral and Regional Cooperation to Mitigate Vector-Borne Diseases in the Mediterranean
The interconnectedness of our world has brought about significant challenges in public health, particularly with the rise of infectious epidemics. Globalization, climate change, and rapid urbanization have created fertile ground for the emergence and spread of diseases, as starkly illustrated by the COVID-19 pandemic. Among these threats, vector-borne diseases transmitted by mosquitoes and ticks...
-
Fiche maladie | 2015.10.06
Leptospirosis
Leptospirosis is a bacterial disease that occurs worldwide. It is transmitted from animals to humans via urine. The main animal reservoirs are rats, but any mammals can carry the bacteria. In humans, leptospirosis is often mild, but it can lead to kidney failure or even death in 5 to 20% of cases.
-
News | 2023.05.23
Creation of an European Biocluster for Emerging Infectious Diseases
The project "Infectious Diseases Cluster" (IDCluster) has been selected for the Healthcare Innovation 2030 plan. This strategy aims to strengthen biomedical research in France. Coordinated by Lyonbiopôle and supported by the Auvergne-Rhône-Alpes region, this European-scale cluster aims to accelerate progress in the field of emerging diseases, by working with the Institut Pasteur among others.
-
News | 2025.03.26
Training the Physician-Scientists of Tomorrow: Institut Pasteur MD-PhD Program
In the face of global health crises and growing public health challenges, strengthening the links between scientific research (both fundamental and applied) and clinical practice has become essential. Recognizing this need, the Institut Pasteur has launched the MD-PhD program as part of its “Pasteur 2030” strategic plan, aiming to engage the Institute in training physician-scientists who can...
-
Document de presse | 2025.03.31
MOPEVACLAS vaccine candidate for Lassa fever enters clinical trials
After more than 20 years of research on arenaviruses, an Institut Pasteur team led by Sylvain Baize has developed an original vaccine platform known as MOPEVAC, which will strengthen the Institut Pasteur's pandemic preparedness initiatives. A Phase Ia clinical trial led by a research team at the Institut Pasteur is set to begin for the platform's first vaccine candidate, which targets Lassa fever...
-
Fiche maladie | 2015.10.06
Chagas disease
Chagas disease, also known as American trypanosomiasis, is a chronic infection caused by the parasite Trypanosoma cruzi. It primarily occurs in Latin America, where it represents a major public health problem, but cases have also been identified in other regions. Chagas disease is mainly transmitted by triatomine bugs, although it can also be contracted through blood/blood products and mother-to-...
-
News | 2026.01.22
Legionellosis: a novel method to predict the fate of infected cells
Scientists have combined metabolic analysis, state-of-the-art microscopic techniques and artificial intelligence to successfully predict the outcome of infection with Legionella pneumophila, which causes legionellosis, at the single-cell level. This method could be applied to other pathogenic bacteria in future.
-
Article | 2017.06.19
Call For Projects Fiocruz - Institut Pasteur – USP
The Call for Proposals Brings Together at Least One Researcher or Team from Each Partner Institution: Oswaldo Cruz Foundation (Fiocruz), one of the Pasteur Network members and the University of São Paulo (USP).